Barrow Robert: insider trades.
Barrow Robert reported 5 non-derivative transactions on 4 SEC ownership filings in Q3 2026: 0 open-market purchases and 2 sales ($1.9M), across 1 company.
- Transactions
- 5
- Purchases (P)
- 0
- Sales (S)
- 2
- Companies
- 1
- Name as filed
- Barrow Robert
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Definium Therapeutics, Inc. (DFTX) | Director, Officer · Chief Executive Officer | 5 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-25 | Definium Therapeutics, Inc. | S | 31,550 | $36.57 | 2,213,090 | Form 4 |
| 2026-09-14 | Definium Therapeutics, Inc. | A | 750,000 | $0 | 2,244,640 | Form 4 |
| 2026-09-03 | Definium Therapeutics, Inc. | S | 19,023 | $37.94 | 1,494,640 | Form 4 |
| 2026-09-02 | Definium Therapeutics, Inc. | A | 40,000 | $0 | 1,513,663 | Form 4 |
| 2026-08-12 | Definium Therapeutics, Inc. | A | 375,000 | $0 | 1,473,246 | Form 4 |
Questions
What stock did Barrow Robert buy or sell?
Barrow Robert reported 5 non-derivative transactions on 4 SEC ownership filings in Q3 2026: 0 open-market purchases and 2 sales ($1.9M), across 1 company.
Is Barrow Robert the same person as other filers with this name?
This page covers SEC CIK 1897557 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/barrow-robert-1897557.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.